Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Erick J. Lucera
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr. Lucera brings more than thirty years of financial, operational and investment experience in the life science industry to Dyne and will be instrumental in helping the company advance two late-stage clinical programs toward potential regulatory approvals.
'Erick's deep industry expertise and extensive track record in financial strategy, efficient capital allocation and operations make him a vital addition to our team,' said John Cox, president and chief executive officer of Dyne. 'His leadership will be critical as we prepare for the potential expedited approvals and commercialization of our DM1 and DMD programs.'
'I am deeply impressed by Dyne's platform, and its ability to execute on its goals to rapidly advance clinical programs,' said Mr. Lucera. 'With two highly promising late-stage clinical assets and a strong pipeline, the company is poised to create significant value for both patients and shareholders. It's exciting to join Dyne at this pivotal moment, and I look forward to applying my experience to help Dyne effectively deliver on all of the valuable opportunities ahead.'
Erick joins Dyne from Editas Medicine, where he served as CFO, overseeing financial strategy, financing initiatives, strategic licensing transactions and infrastructure scaling to prepare the company for commercialization. Previously, as CFO of AVEO Pharmaceuticals, he led its transition from a clinical-stage company to commercialization, drove R&D pipeline growth and played a key role in its acquisition by LG Chem. Before that, he was CFO, treasurer, and secretary at Valeritas, where he helped develop the company's global distribution strategy. Prior to Valeritas, Erick was CFO, treasurer, and secretary at Viventia Bio, where he prepared the company for an initial public offering. Erick also served as Vice President of corporate development at Aratana Therapeutics, securing multiple financings and managing licensing transactions and acquisitions to strengthen the company's pipeline. Earlier in his career, he spent 15 years in investment management as a healthcare analyst. He holds a Certificate in Public Health from Harvard University, an MS in finance from Boston College, an MBA from Indiana University and a BS in accounting from the University of Delaware.
About Dyne Therapeutics
Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, and the potential of DYNE-101 and DYNE-251, and the availability of expedited approval pathways constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.
Contacts:
InvestorsMia Tobiasir@dyne-tx.com781-317-0353
MediaStacy Nartkersnartker@dyne-tx.com781-317-1938
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e655e1a8-1957-4a00-8932-411404b68d94Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
The $1.3 Billion Health-Tech IPO Everyone Missed--Until It Soared 21% on Day One
Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That move gives the digital chronic-care startup a market cap of roughly $1.3 billion. The $150 million raise was more than just well receivedinvestor demand came in more than 15x oversubscribed, with most allocations going to a concentrated group of institutional buyers. It's another sign that appetite for health-tech IPOs is heating up again. U.S. listings have raised nearly $25 billion year-to-date, and early-stage healthcare names are up an average of 18% since listing. Founded in 2011, Omada offers virtual care between doctor visitsfocused on diabetes, obesity, hypertension, and joint pain. What sets it apart? It's not chasing the GLP-1 gold rush. Instead, Omada supports people already on those drugs, helping them manage side effects, nutrition, and post-treatment maintenance. About 50,000 of its 679,000 members are on GLP-1s. CEO Sean Duffy told Bloomberg that while AI powers much of the back-end, real human interaction is what drives results. Our members tell us they want a personand I have yet to see anyone that feels accountable to ChatGPT, he said. Revenue for Q1 2025 came in just under $55 millionup from $35.1 million a year agowhile net losses narrowed by more than half to $9.4 million. That improving financial picture, combined with a clear niche in chronic care, could be what's drawing top-tier investors. Revelation Partners, Andreessen Horowitz, Fidelity, and USVP are all among the largest shareholders. The IPO was led by Morgan Stanley, Goldman Sachs, and JPMorgan. OMDA now trades on the Nasdaq Global Marketand it's one more sign that digital health might be staging a real comeback. This article first appeared on GuruFocus.
Yahoo
31 minutes ago
- Yahoo
Omada Health Soars 42% in Nasdaq Debut After $150 Million IPO
Omada Health (OMDA, Financials) surged 42% in its Nasdaq debut Friday after the virtual chronic care company priced its initial public offering at $19 per share, raising $150 million and securing a valuation just above $1 billion. The stock opened at $23 and climbed quickly past $27. Warning! GuruFocus has detected 8 Warning Sign with X. Founded in 2012, Omada offers virtual programs for chronic conditions including prediabetes, diabetes, and hypertension. The IPO, which sold 7.9 million shares, is part of a recent resurgence in health and tech listings, following last month's debut of Hinge Health and Thursday's surge in Circle Internet shares. In its prospectus, Omada reported Q1 revenue jumped 57% year over year to $55 million, while full-year 2024 revenue rose 38% to $169.8 million. The company narrowed its net loss in the most recent quarter to $9.4 million from $19 million a year earlier. Major outside shareholders include U.S. Venture Partners, Andreessen Horowitz, and Fidelity's FMR LLC, each holding a 9% to 10% stake. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Grab's $7B Mega Move Could Flip Southeast Asia's Tech Empire--But Indonesia Might Block It
Grab (NASDAQ:GRAB) is quietly pushing forward on what could be one of Southeast Asia's biggest tech shakeupsa $7 billion move to acquire rival GoTo. After years of circling each other, the two ride-hailing and food delivery giants are now refining a two-step deal: GoTo could first absorb Grab's Indonesia unit, then Grab would swoop in for control of the merged business. But it's not just about market strategy. The deal faces serious political and regulatory headwinds, especially in Indonesia, where a merger would concentrate 6070% of the on-demand market in one player's hands. Warning! GuruFocus has detected 5 Warning Sign with GRAB. Enter DanantaraIndonesia's sovereign wealth fundwhich has kicked off early-stage talks to buy a minority stake in the new entity. That move could help ease nationalist fears over foreign dominance, job losses, and rising consumer costs. For President Prabowo's government, which has been flexing its populist muscles with wage hikes, subsidy boosts, and demands for driver bonuses, having a local backer in the mix might be a political win. For Grab, it's a potential green light. But the clock is ticking. Any deal still hinges on clearance from Indonesia's antitrust watchdog, and regulatory nerves remain high. Meanwhile, the market dynamics are shifting fast. Grab's revenue in Indonesia rose just 6.3% in 2024its slowest in Southeast Asiawhile GoTo has already exited Vietnam and Thailand. A tie-up would give Grab more firepower in Indonesia's 275-million-strong market, just as newer players like InDrive and Maxim try to muscle in. The stakes? If Danantara comes onboard, the merger could reshape Southeast Asia's tech landscape. If not, Grab might have to find another way into the driver's seat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
